Skip to main content
UniHealth

Doctor search

Antonio Marcilio Padula Omuro, MD

Neurology · Stanford

NPI 1912175134

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
1 carrier
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

12 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Omuro’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026

State licence records

1 licence

  • Florida ME131052Medical Doctor · since 2017 · expires 2019-01-31
    RetiredNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

School, training and certification

1 placement

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Education

  • Universidade De Sao Paulo · MD1989–1994Medical school

Residency and fellowship

  • Memorial Sloan Ketterig, OncologyNEW YORK, NY · 2002–2004

What else the board holds

Also licensed in

States the clinician told their board they are also licensed in. Only the states we check are verified.

New York

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$7,534

Medicare paid this office $7,534 for 28 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)13$3,118$173
Long return visit (40+ min)13$2,237$118
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's13$300$15
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's11$240$15

Who their Medicare patients are

28 Original Medicare patients in 2024. Average age 67 · Women 50% · Health risk score 2.08. Above the middle of the specialty; the typical neurology clinician is at 1.61.

Conditions among them: High blood pressure 50%.

The office billed $29,822, Medicare allowed $9,728 and paid $7,534; for 83 services of 4 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242883672.08$29,822$7,534
202351123712.31$60,175$14,445
202253122722.01$62,450$15,007
202143131701.97$65,170$16,337
202034124712.11$58,195$12,411
20192260701.64$29,840$6,587
20182987651.43$40,422$8,706
20174276692.90$40,904$7,049
201695214692.31$120,650$20,876
2015100216692.19$118,925$21,697
2014146258702.47$124,115$25,063
201393159682.35$81,100$16,298

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 1 service

Original Medicare services billed in 2023
Long return visit (40+ min)41$10,686$120

2022: 2 services

Original Medicare services billed in 2022
Long return visit (40+ min)38$10,295$120
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,471$165

2021: 2 services

Original Medicare services billed in 2021
Long return visit (40+ min)30$11,301$126
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,218$171

2020: 2 services

Original Medicare services billed in 2020
Long return visit (40+ min)19$4,146$96
Long return visit (40+ min)19$3,298$94

2019: 1 service

Original Medicare services billed in 2019
Long return visit (40+ min)12$1,519$95

2018: 2 services

Original Medicare services billed in 2018
Long return visit (40+ min)20$5,691$93
New patient visit (60+ min)16$2,335$146

2016: 5 services

Original Medicare services billed in 2016
Long return visit (40+ min)32$7,650$92
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$5,422$92
Initial hospital care with moderate level of medical decision making at least 75 minutes16$3,052$180
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes17$1,542$91
Return visit (30+ min)16$1,403$64

2015: 5 services

Original Medicare services billed in 2015
Long return visit (40+ min)41$7,238$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$6,009$92
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,069$181
New patient visit (60+ min)17$2,410$142
Return visit (30+ min)15$1,163$68

2014: 6 services

Original Medicare services billed in 2014
Long return visit (40+ min)50$9,131$93
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes28$5,144$90
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes45$4,010$89
New patient visit (60+ min)18$2,671$148
Initial hospital care with moderate level of medical decision making at least 75 minutes14$2,486$178
Return visit (30+ min)12$825$69

2013: 5 services

Original Medicare services billed in 2013
Long return visit (40+ min)40$6,057$89
Initial hospital care with moderate level of medical decision making at least 75 minutes26$4,444$171
New patient visit (60+ min)13$1,856$143
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$1,828$87
Return visit (30+ min)15$1,364$62

Money from drug and device companies

$2,500 in 2024

Industry payments by year
202411$2,500$2,500
202111$2,000$2,000
202013$7,000$7,150
2019210$5,375$6,688

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Telix PharmaceuticalsIlluccix$2,500
1 payment
  • Consulting for Illuccix · 2024-03-12 · $2,500
See the published payment
Every published payment
Telix PharmaceuticalsConsulting · 2024-03-12Illuccix$2,500
See earlier years (2021, 2020, 2019)

2021: $2,000

Payments by company in 2021
Merck Sharp & DohmeKeytruda$2,000
1 payment
  • Consulting for Keytruda · 2021-01-20 · $2,000

2020: $7,150

Payments by company in 2020
Merck Sharp & DohmeNone$7,150
3 payments
  • Consulting · 2020-06-24 · $1,500
  • Travel · 2020-01-29 · $150
  • Consulting · 2020-01-29 · $5,500

2019: $6,688

Payments by company in 2019
BTG InternationalVoraxaze$6,495
6 payments
  • Paid to speak or teach for Voraxaze · 2019-04-26 · $5,375
  • Meals for Voraxaze · 2019-04-26 · $30
  • Travel for Voraxaze · 2019-04-26 · $312
  • Travel for Voraxaze · 2019-02-11 · $312
  • Travel for Voraxaze · 2019-02-11 · $227
  • Meals for Voraxaze · 2019-02-11 · $238
Merck Sharp & DohmeNone$193
4 payments
  • Meals · 2019-11-21 · $64
  • Meals · 2019-11-21 · $30
  • Meals · 2019-11-21 · $49
  • Meals · 2019-11-21 · $50

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme Corporation · A Proof-of-Concept, Pilot Study of Pembrolizumab Mk-3475 in Patients With Recurrent Glioblastoma With A Hypermutator Phenotype · 2019Their institution$95,500
Servier BioInnovation · Study of Vorasidenib, Ag-881, in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation, Indigo · 2023Their institution$63,675
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2023Their institution$32,585
Servier Pharmaceuticals LLC · Study of Vorasidenib (Ag-881) in Participants With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation (Indigo) · 2021Their institution$24,534
Agios Pharmaceuticals, Inc. · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Vorasidenib in Subjects With Recurrent, Non-Enhancing, Low-Grade Glioma With An Idh1 Or Idh2 Mutation · 2020Their institution$18,844
Servier BioInnovation · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Ag-881 in Subjects With Residual Or Recurrent Grade 2 Glioma With An Idh1 Or Idh2 Mutation · 2024Their institution$15,626
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2024Their institution$9,147
Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2022Their institution$727

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
73.6 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1912175134
Licence
CT 62031, FL ME131052, NY 247562Florida ME131052: Retired
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
Yes
Taxonomy
Neurology (2084N0400X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2008-02-11
NPI last updated
2024-06-27
NPI record certified
2024-06-27

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 35 Park St Fl 8, New Haven, CT, 06519